EMD

CN Continues to Advance Decarbonization Efforts with EMD® Mainline Hybrid Locomotive from Progress Rail

Retrieved on: 
Friday, April 5, 2024
CNI, CDP, S&P Global, Climate change, Transport, CNR, Progress Rail, Carbon, TSX, Caterpillar Inc., EMD, Weather, Renewable energy

MONTREAL, April 05, 2024 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) is proud to announce the purchase of its first hybrid diesel-battery electric mainline locomotive from Progress Rail, a Caterpillar Company, as part of its decarbonization plans. The EMD® will be tested to understand the potential impact and opportunity related to retrofitting a larger portion of the Company’s fleet. CN is collaborating on this initiative with the Province of British Columbia who awarded approximately $3.2 million to the Company under the Clean BC Go Electric Commercial Vehicle Pilots Program.

Key Points: 
  • MONTREAL, April 05, 2024 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) is proud to announce the purchase of its first hybrid diesel-battery electric mainline locomotive from Progress Rail, a Caterpillar Company, as part of its decarbonization plans.
  • The EMD® will be tested to understand the potential impact and opportunity related to retrofitting a larger portion of the Company’s fleet.
  • The testing will increase CN’s and the rail industry’s knowledge on battery technology and more specifically, on the impact of alternative propulsion technology on mainline locomotives.
  • “CN is committed to supporting the transition to a net-zero economy and proud of the progress we’ve made so far on our decarbonization journey.

Global Electronic Warfare Market Size Expected to Reach $24.76 Billion by 2029

Retrieved on: 
Tuesday, March 26, 2024
Knowledge, CDR, Lockheed, Artificial intelligence, EVO, L3Harris Technologies, Air force, General Dynamics, PCM, USD, Lockheed Martin, Research, NOC, Pratt & Whitney, Partnership, Risk, PALM, Electronics, Radio, The, KULR, F-35, General Dynamics Land Systems, LMT, News, Acquisition, Missile Defense Agency, NGI, Northrop Grumman, Engineering, ICBM, Critical, Element, Growth, MDA, United, Marketing, Grumman, EMD, Jet fuel

The electronic warfare market is marked by the presence of global and local players competing in technology and product offerings; Some major market players are Lockheed Martin Corporation, L3Harris Technologies, Inc., Northrop Grumman Corporation, RTX Corporation, and Leonardo S.p.A., amongst others.

Key Points: 
  • The electronic warfare market is marked by the presence of global and local players competing in technology and product offerings; Some major market players are Lockheed Martin Corporation, L3Harris Technologies, Inc., Northrop Grumman Corporation, RTX Corporation, and Leonardo S.p.A., amongst others.
  • A report from Mordor Intelligence projected that the Electronic Warfare Market size is estimated at USD 19.30 billion in 2024, and is expected to reach USD 24.76 billion by 2029, growing at a CAGR of 5.11% during the forecast period (2024-2029).
  • Mordor Intelligence concluded: “Various players in the market are investing significantly in research and developing advanced next-generation warfare products having higher electromagnetic capabilities.
  • According to Straits Research , the global electronic warfare market size is estimated to reach an expected value of USD 27.79 billion by 2030, registering a CAGR of 5.8% during the forecast period of 2022 to 2030.

AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors

Retrieved on: 
Wednesday, February 28, 2024
Research, Doctor of Philosophy, General partnership, Drug development, Growth, Frustration, University, Chronic pain, SUNY, Biomedical sciences, Epilepsy, Neurology, Rett syndrome, Smith, Kline & French, Acadia Pharmaceuticals, School, University at Buffalo, Biotechnology, ATyr Pharma, Health, Neurotoxicity, Cell, Therapy, DSM-IV codes, Brain, Neuropharmacology, Proteostasis, Amathus, Record, Drug discovery, Peripheral neuropathy, MPS, Physics, OPKO Health, Genomics, Acquisition, EMD, LoDo, Denver, MD, Organoid, Multiple sclerosis, Prevalence, Brown University, Brandeis University, Serono, Patient, Disease, GSK plc, Pharmaceutical industry

Dr. Pfost noted, “AxoSim embodies the entrepreneur’s sweet spot--when market need, technological innovation, timing and team all align. The growing prevalence of neurological diseases places enormous burdens on patients, their families and society. Yet despite billions in investment, neurology R&D continues to disappoint. AxoSim’s transformational approach addresses a key contributor to these failures—the lack of relevant disease models—by providing functional human data from its microphysiological system (MPS) organoid technologies early in the process. AxoSim aims to become an industry leader in helping to deliver urgently needed new drugs and I welcome the opportunity to contribute to its success.”

Key Points: 
  • Dr. Pfost and Dr. Weiner have decades of experience in building successful biotechnology companies spanning therapeutics, diagnostics and life science tools and technologies.
  • “Our recent acquisition of a third platform technology positions AxoSim for growth, and we are fortunate to have these two talented industry veterans assuming key leadership roles,” said Lowry Curley, PhD, co-founder and Chief Executive Officer of AxoSim.
  • “Dale and Dave bring successful track records in building life sciences businesses, with broad and complementary skill sets.
  • Dale’s work in life science tools and venture finance is highly relevant, as is Dave’s expertise in leading neurological drug discovery and clinical development.

Northrop Grumman Advances Sentinel Design Phase With Key Tests

Retrieved on: 
Tuesday, February 20, 2024
Engineering, EMD, Air force, NOC, Risk, ICBM, Element, Grumman, Northrop Grumman, The, Jet fuel

ROY, Utah, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Northrop Grumman Corporation (NYSE: NOC) successfully completed tests of several crucial elements of the Sentinel intercontinental ballistic missile (ICBM), marking significant progress for the program in its engineering, manufacturing and development phase.

Key Points: 
  • ROY, Utah, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Northrop Grumman Corporation (NYSE: NOC) successfully completed tests of several crucial elements of the Sentinel intercontinental ballistic missile (ICBM), marking significant progress for the program in its engineering, manufacturing and development phase.
  • The shroud fly-off and missile modal tests were part of the company’s engineering, manufacturing, and development (EMD), or design, contract for Sentinel.
  • Northrop Grumman is closely partnered with the Air Force as the EMD phase progresses and key milestones are achieved.
  • (Photo Credit: Northrop Grumman)
    Sarah Willoughby, vice president and program manager, Sentinel, Northrop Grumman: “Working with the Air Force and our team of suppliers, we put key elements of the missile’s hardware to the test to mature our design and lower risk.

WiMi Developed Efficient Prediction Models for Cryptocurrency Markets Based on Machine Learning

Retrieved on: 
Tuesday, February 27, 2024
Cloud, Bitcoin, EMD, Algorithm, Artificial intelligence, WIMI, VMD, Overalls, Holography, Face, ELM, Extreme learning machine, Machine learning, Augmented reality, Deep learning, LSTM, Cryptocurrency

Based on machine learning, deep learning and other techniques, it focuses on developing efficient forecasting models applicable to the cryptocurrency market.

Key Points: 
  • Based on machine learning, deep learning and other techniques, it focuses on developing efficient forecasting models applicable to the cryptocurrency market.
  • Therefore, WiMi chose a multi-scale analysis approach, matching different machine learning algorithms with corresponding multi-scale components to construct a more comprehensive cryptocurrency price prediction model.
  • WiMi put its emphasis on the hybrid LSTM-ELM model that combines advanced methods such as multi-scale analysis, artificial intelligence, and signal decomposition.
  • Deep learning algorithms enhanced data learning capabilities for the model, allowing it to better understand and adapt to the nonlinear characteristics of the cryptocurrency market.

Maximus Announces New Growth Federal Leadership Team Across Civilian, Health, and Defense Markets

Retrieved on: 
Wednesday, January 24, 2024
Public Policy, Government, Other Professional Services, Software, White House, Federal Government, Consulting, Data Management, Professional Services, Technology, Patient, DOE, Federal, EMD, AI, CX, MMS, Air force, Defense, Machine learning, Growth, Management

Maximus (NYSE: MMS), a leading employer and provider of government services worldwide, today announced a new Federal growth leadership team managing three key verticals across Civilian, Health, and Defense.

Key Points: 
  • Maximus (NYSE: MMS), a leading employer and provider of government services worldwide, today announced a new Federal growth leadership team managing three key verticals across Civilian, Health, and Defense.
  • “The Federal team delivers exceptional services, technology, and approaches to federal agencies that turn their ideas into reality,” said Teresa Weipert, General Manager of Maximus’ Federal Services segment.
  • “We’ve reached a pivotal moment in federal technology as emerging technologies, like AI and machine learning, are opening up so many possibilities when it comes to modernization.
  • Rosser comes to Maximus after several leadership roles across the government contracting market, including with Deloitte and Booz Allen Hamilton.

Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma.

Retrieved on: 
Monday, January 29, 2024
The Lancet, Hope, CMC, Patient, ISS, MRD, Therapy, GPRC5D, ASCO, EMD, CRS, IND, Food, Multiple myeloma, EHA, FDA, Investigational New Drug, BCMA, POLARIS, NMPA, Pharmaceutical industry

OriCAR-017 is a chimeric antigen receptor (CAR) T cell therapy targeting GPRC5D.

Key Points: 
  • OriCAR-017 is a chimeric antigen receptor (CAR) T cell therapy targeting GPRC5D.
  • The therapy leverages Oricell's proprietary platforms including Ori®Ab antibodies, Ori®CAR construct and unique CMC know-how to achieve optimal binding and superior persistence and anti-tumor efficacy out of rejuvenated CAR-T cells.
  • The IND enables Oricell to initiate the clinical development for OriCAR-017 in the US immediately.
  • "The evidenced superior safety, efficacy and durability profile of OriCAR-017 is truly exciting and will significantly benefit multiple myeloma patients on a global scale.

Coastal Medical Transportation Systems Reflects on Another Year of Rapid Growth

Retrieved on: 
Wednesday, January 3, 2024
Transportation, Practice Management, Travel, Managed Care, Other Health, Health, Other Transport, General Health, Transport, Public Safety, Public Policy, Government, EPOC, CMTS, Boston Metro, Acquisition, Emergency medical technician, EMD, Northeastern University, Investment, Patient, Ambulance, Nursing

Coastal Medical Transportation Systems (CMTS), a privately owned and operated medical transportation company dedicated to providing the highest quality of care with compassion, dignity and respect for customers and their patients, today announced several significant company milestones that in culmination represent another banner year for the organization.

Key Points: 
  • Coastal Medical Transportation Systems (CMTS), a privately owned and operated medical transportation company dedicated to providing the highest quality of care with compassion, dignity and respect for customers and their patients, today announced several significant company milestones that in culmination represent another banner year for the organization.
  • Most recently, the company extended its 9-1-1 contract with Dedham, MA, ensuring that the community is supported by CMTS’ Emergency Medical Dispatch (EMD) services for an additional five years.
  • In addition, all company transport was upfitted with Samsara Telematics Systems and Mobilis mobile data systems.
  • “Coastal Medical Transportation Systems is thrilled to enter 2024 with tremendous momentum including explosive customer growth and aggressive talent acquisition,” said Alexandre Theoharidis, CEO of Coastal Medical Transportation Systems.

Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 11, 2023
Patient, Quality of life, Division, Death, Relapse, Pancytopenia, Cytokine release syndrome, Disease, LBL, Blood, EMD, SAN, Gene, Graft-versus-host disease, EMRA, CRC, ASH, CD38, Oncology, M.D, CRS, T-ALL, Fungal infection, Cell, Medicine, Phenotype, Pharmaceutical industry

“For a disease that disproportionately affects younger individuals, the need to find better treatments feels especially urgent,” said Armin Ghobadi, M.D, associate professor of medicine and clinical director of Center for Gene and Cellular Immunotherapy (CGCI) in the Division of Medical Oncology at the Washington University School of Medicine in St. Louis. “It’s encouraging to see positive momentum -- with favorable tolerability and efficacy data continuing to be reported as the study has expanded to include more patients with such difficult-to-treat blood cancers.”

Key Points: 
  • An investigational allogeneic CAR-T cell therapy, WU-CART-007 is being studied for the treatment of patients with relapsed or refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL).
  • In the latest update, an additional 13 patients were treated with WU-CART-007, which showed clinically acceptable safety profiles and preliminary evidence of anti-leukemic activity, demonstrating a notable clinical improvement.
  • Positive and consistent data from the WU-CART-007 Phase 1/2 trial collectively underscore its potential to address unmet medical needs for difficult-to-treat blood cancers as it advances to the next crucial phase of development.
  • In evaluable patients at DL≥ 2 (18/22), the Composite Complete Remission Rate (CRc) in patients was 67%.

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023

Retrieved on: 
Sunday, December 10, 2023
Associate, Food, Bone marrow, MRD, FDA, Royal College of Pathologists, CRi, Cancer Institute, Multiple myeloma, BCMA, EMD, Doctor of Philosophy, Society, Biologics license application, Therapy, ASH, EFS, University College London, Toxicity, CRS, Webcast, Patient, CD19, Safety, ALL, B-ALL, UCL, BLA, Pharmaceutical industry

Finally, in an oral presentation pre-clinical and Phase I clinical data from AUTO8, a BCMA/CD19 co-targeting CAR T cell candidate, evaluated in patients with refractory multiple myeloma.

Key Points: 
  • Finally, in an oral presentation pre-clinical and Phase I clinical data from AUTO8, a BCMA/CD19 co-targeting CAR T cell candidate, evaluated in patients with refractory multiple myeloma.
  • “The FELIX study, with 127 patients, is one of the largest CAR T cell studies in adults with r/r B-ALL.
  • A high proportion of patients responded, with many responses sustained, particularly in patients with low or intermediate disease-burden at lymphodepletion.
  • Cellular kinetic data shows high expansion and long-term persistence of CAR T cells in most responders.